Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Valveva Moves a Publication Related to Lyme Disease and Falls on the Stock Exchange

Summary by L'AGEFI
Biotech now plans to reveal the results of its Phase 3 study for its treatment of tick-induced disease in the first half of 2026. It has also contracted a new $500 million loan.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

BFM BourseBFM Bourse

Valveva: with the Postponement of Crucial Clinical Results and the Lowering of Its Forecasts, Valneva Falls on the Stock Exchange

https://www.tradingsat.com/valneva-FR0004056851/actualites/valneva-with-the-report-of-results-clinical-crucial-and-l-lower-of-its-previsions-valneva-chute-en-bourse-1147866.html

Read Full Article
L'AGEFIL'AGEFI

Valveva Moves a Publication Related to Lyme Disease and Falls on the Stock Exchange

Biotech now plans to reveal the results of its Phase 3 study for its treatment of tick-induced disease in the first half of 2026. It has also contracted a new $500 million loan.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

L'AGEFI broke the news in on Tuesday, October 7, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Biotech icon

Biotech

France icon

France

News
For You
SearchBlindspotLocal